Drug
Ceralasertib clinical trials
Also written AZD6738.
Keep track of what changes. Save the ceralasertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2019 (6)
| Year | Studies |
|---|---|
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 24
AstraZeneca (12) · National Cancer Institute (NCI) (3) · Samsung Medical Center (3) · Institute of Cancer Research, United Kingdom (2) · Massachusetts General Hospital (1) · Dana-Farber Cancer Institute (1) · Muhammad Furqan (1) · University of Michigan Rogel Cancer Center (1)
Often tested with
Tested in the same studies.
Durvalumab (14) · Olaparib (13) · Capivasertib (5) · Adavosertib (4) · Vistusertib (3) · AZD 6244 (3) · Trastuzumab deruxtecan (2) · Danvatirsen (2)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses ceralasertib is read from its arms, and is right about nine times in ten.
Testing it · 37
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04090567Written as Ceralasertib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Ceralasertib
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingPhase 1University of LeedsNCT04550104Written as Ceralasertib
- Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenRecruitingPhase 2Mario Negri Institute for Pharmacological ResearchNCT06680050Written as Ceralasertib
- Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingPhase 2IFOM ETS - The AIRC Institute of Molecular OncologyNCT05582538Written as Ceralasertib
- PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingPhase 2Institute of Cancer Research, United KingdomNCT03740893Written as AZD6738
- AZD6738 Plus Durvalumab in Biliary Tract CancerRecruitingPhase 2Seoul National University HospitalNCT04298008Written as AZD6738
- To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active, not recruitingPhase 2AstraZenecaNCT03330847Written as Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
- AZD6738 for Patients With Progressive MDS or CMMLActive, not recruitingPhase 1Massachusetts General HospitalNCT03770429Written as AZD6738
- Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT04417062Written as Ceralasertib
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT06732401Written as Ceralasertib
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingPhase 2AstraZenecaNCT05941897Written as Ceralasertib
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04704661Written as Ceralasertib
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingPhase 2Muhammad FurqanNCT04699838Written as Ceralasertib
- Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of CeralasertibTerminatedPhase 1AstraZenecaNCT06754761Written as [14C] AZD6738
- A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursActive, not recruitingPhase 1AstraZenecaNCT05514132Written as Ceralasertib
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03878095Written as Ceralasertib
- A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug ZTerminatedPhase 1AstraZenecaNCT06929260Written as Ceralasertib
- A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingPhase 3AstraZenecaNCT05450692Written as Ceralasertib
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935Written as AZD6738
See all 37 studies that test ceralasertib →
Given in every arm · 8 — ceralasertib is usual care beside what is tested
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingPhase 2SWOG Cancer Research NetworkNCT06769126Written as Ceralasertib
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03579316Written as Ceralasertib
- A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingPhase 1Acerta Pharma BVNCT03328273Written as Ceralasertib
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingPhase 2Rahul AggarwalNCT03682289Written as Ceralasertib
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingPhase 2Institute of Cancer Research, United KingdomNCT04065269Written as Ceralasertib
- Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid TumoursStatus unknownPhase 1Royal Marsden NHS Foundation TrustNCT02223923Written as AZD6738
- A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionActive, not recruitingPhase 2AstraZenecaNCT05061134Written as Ceralasertib
- DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract CancerActive, not recruitingPhase 2Seoul National University HospitalNCT04298021Written as AZD6738
Codes
What other systems call ceralasertib · ClinicalTrials.gg INT000556
- MeSH (NLM) C000611951ceralasertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 85RE35306ZCERALASERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27896182ceralasertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C111993CeralasertibOne source FDA
- DrugBank DB14917One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000611951 | ceralasertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 85RE35306Z | CERALASERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27896182 | ceralasertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C111993 | Ceralasertib | One source FDA |
| DrugBank | DB14917 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.